Vertex Pharmaceuticals is a leading biotechnology company based in the United States that focuses on developing small-molecule drugs for treating severe diseases. With a low risk ESG score of 19.3, Vertex is known for its groundbreaking therapies for cystic fibrosis such as Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio. The company has expanded its portfolio to include Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. In addition, Vertex is researching nonopioid treatments for pain management and small-molecule inhibitors for kidney diseases. Moreover, Vertex is exploring cell therapies to potentially cure type 1 diabetes, making it a pioneer in sustainable healthcare solutions.